$FNCH
Finch Therapeutics Group, Inc.

2023 Q2 Form 10-Q Financial Statement

#000095017023020080 Filed on May 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $0.00 $107.0K $354.0K
YoY Change -100.0% -69.77% -90.04%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.877M $9.617M $9.404M
YoY Change 8.73% 2.26% 106.68%
% of Gross Profit
Research & Development $203.0K $8.588M $15.53M
YoY Change -98.54% -44.7% 19.69%
% of Gross Profit
Depreciation & Amortization $57.00K $1.367M $1.331M
YoY Change -95.82% 2.7% 261.68%
% of Gross Profit
Operating Expenses $9.881M $67.48M $24.93M
YoY Change -57.02% 170.64% 42.26%
Operating Profit -$9.881M -$67.38M -$24.58M
YoY Change -56.33% 174.1% 75.9%
Interest Expense $420.0K $425.0K $13.00K
YoY Change -746.15% 3169.23%
% of Operating Profit
Other Income/Expense, Net $2.931M -$25.00K $13.00K
YoY Change -4228.17% -292.31% -285.71%
Pretax Income -$6.950M -$67.40M -$24.57M
YoY Change -69.38% 174.35% 75.72%
Income Tax $0.00 -$3.461M $0.00
% Of Pretax Income
Net Earnings -$6.950M -$63.94M -$24.57M
YoY Change -69.38% 160.26% 75.72%
Net Earnings / Revenue -59756.07% -6939.83%
Basic Earnings Per Share -$4.33 -$1.33 -$0.52
Diluted Earnings Per Share -$4.33 -$1.33 -$516.9K
COMMON SHARES
Basic Shares Outstanding 48.14M 48.14M 47.53M
Diluted Shares Outstanding 1.605M 48.09M 47.53M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $34.05M $41.68M $106.9M
YoY Change -67.47% -61.02% -44.6%
Cash & Equivalents $34.10M $41.70M $106.9M
Short-Term Investments
Other Short-Term Assets $2.448M $1.606M $15.55M
YoY Change -57.04% -89.67% 418.2%
Inventory
Prepaid Expenses
Receivables $0.00 $100.0K $200.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $36.50M $43.40M $122.6M
YoY Change -66.98% -64.62% -38.16%
LONG-TERM ASSETS
Property, Plant & Equipment $732.0K $1.248M $19.41M
YoY Change -96.03% -93.57% 18.06%
Goodwill $18.06M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $200.0K $4.542M
YoY Change -100.0% -95.6% 2002.78%
Total Long-Term Assets $30.36M $35.64M $81.98M
YoY Change -74.22% -56.52% 21.26%
TOTAL ASSETS
Total Short-Term Assets $36.50M $43.40M $122.6M
Total Long-Term Assets $30.36M $35.64M $81.98M
Total Assets $66.86M $79.04M $204.6M
YoY Change -70.72% -61.37% -23.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $432.0K $2.553M $4.765M
YoY Change -57.35% -46.42% 22.87%
Accrued Expenses $9.143M $10.65M $12.02M
YoY Change -35.48% -11.39% 155.79%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.575M $13.21M $16.79M
YoY Change -36.94% -21.33% 45.94%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.575M $13.21M $16.79M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $38.96M $46.09M $24.84M
YoY Change -43.7% 85.52% -6.24%
SHAREHOLDERS EQUITY
Retained Earnings -$344.9M -$339.6M -$185.6M
YoY Change 65.63% 83.0% 58.85%
Common Stock $372.8M $372.5M $365.4M
YoY Change 1.49% 1.96% 2.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $27.89M $32.95M $179.8M
YoY Change
Total Liabilities & Shareholders Equity $66.86M $79.04M $204.6M
YoY Change -70.72% -61.37% -23.06%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$6.950M -$63.94M -$24.57M
YoY Change -69.38% 160.26% 75.72%
Depreciation, Depletion And Amortization $57.00K $1.367M $1.331M
YoY Change -95.82% 2.7% 261.68%
Cash From Operating Activities -$9.157M -$13.38M -$25.65M
YoY Change -42.19% -47.82% 68.57%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $14.00K $909.0K
YoY Change -100.0% -98.46% -89.71%
Acquisitions
YoY Change
Other Investing Activities $1.270M $0.00
YoY Change -100.0%
Cash From Investing Activities $1.270M -$14.00K -$909.0K
YoY Change -242.06% -98.46% -89.7%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.000K -16.16M 5.000K
YoY Change -99.97% -323280.0% -100.0%
NET CHANGE
Cash From Operating Activities -9.157M -13.38M -25.65M
Cash From Investing Activities 1.270M -14.00K -909.0K
Cash From Financing Activities 4.000K -16.16M 5.000K
Net Change In Cash -7.883M -29.55M -26.55M
YoY Change 302.6% 11.31% -128.45%
FREE CASH FLOW
Cash From Operating Activities -$9.157M -$13.38M -$25.65M
Capital Expenditures $0.00 $14.00K $909.0K
Free Cash Flow -$9.157M -$13.40M -$26.56M
YoY Change -38.73% -49.56% 10.42%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001733257
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P0Y
CY2023Q1 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentNet
CY2022Q4 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentNet
CY2023Q1 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#LiabilitiesCurrent
CY2022Q4 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#LiabilitiesCurrent
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q4 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-40227
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
FINCH THERAPEUTICS GROUP, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-3433558
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
200 Inner Belt Road
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 400
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Somerville
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02143
CY2023Q1 dei City Area Code
CityAreaCode
617
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
229-6499
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2023Q1 dei Trading Symbol
TradingSymbol
FNCH
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
48144924
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41684000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
71038000
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
107000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
144000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1606000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3369000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
43397000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
74551000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1248000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15936000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
31827000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
32752000
CY2023Q1 fnch In Process Research And Development
InProcessResearchAndDevelopment
0
CY2022Q4 fnch In Process Research And Development
InProcessResearchAndDevelopment
32900000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2368000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2568000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
200000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4232000
CY2023Q1 us-gaap Assets
Assets
79040000
CY2022Q4 us-gaap Assets
Assets
162939000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2553000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1097000
CY2023Q1 fnch Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
7400000
CY2022Q4 fnch Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
10161000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3253000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3431000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
13206000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14689000
CY2023Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
0
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
3461000
CY2023Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
14653000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
32882000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
34255000
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
170000
CY2023Q1 us-gaap Liabilities
Liabilities
46088000
CY2022Q4 us-gaap Liabilities
Liabilities
67228000
CY2023Q1 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000
CY2022Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000
CY2023Q1 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2023Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48144924
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48144924
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48053596
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48053596
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-273000
CY2023Q1 fnch Principal Payments On Capital Lease Obligation
PrincipalPaymentsOnCapitalLeaseObligation
4000
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
48000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
48000
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
372484000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
371304000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-339580000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-275641000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
32952000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
95711000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
79040000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
162939000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
107000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
354000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8588000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15530000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9617000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9404000
CY2023Q1 fnch Impairment Of In Process Research And Development
ImpairmentOfInProcessResearchAndDevelopment
32900000
CY2022Q1 fnch Impairment Of In Process Research And Development
ImpairmentOfInProcessResearchAndDevelopment
0
CY2023Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
13141000
CY2022Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2023Q1 us-gaap Restructuring Charges
RestructuringCharges
3236000
CY2022Q1 us-gaap Restructuring Charges
RestructuringCharges
0
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
67482000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
24934000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-67375000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-24580000
CY2023Q1 us-gaap Investment Income Net
InvestmentIncomeNet
425000
CY2022Q1 us-gaap Investment Income Net
InvestmentIncomeNet
13000
CY2023Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1366000
CY2022Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2023Q1 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-137000
CY2022Q1 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1053000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-25000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
13000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-67400000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-24567000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3461000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-63939000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-24567000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-63939000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-24567000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.33
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.33
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.52
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.52
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48085547
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48085547
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47528948
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47528948
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
202224000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
14000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2120000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-24567000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
179791000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
95711000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1180000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-63939000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
32952000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-63939000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-24567000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1367000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1331000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1180000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2120000
CY2023Q1 fnch Impairment Of In Process Research And Development
ImpairmentOfInProcessResearchAndDevelopment
32900000
CY2022Q1 fnch Impairment Of In Process Research And Development
ImpairmentOfInProcessResearchAndDevelopment
0
CY2023Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1366000
CY2022Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2023Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
13141000
CY2022Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2023Q1 fnch Non Cash Interest Expense
NonCashInterestExpense
17000
CY2022Q1 fnch Non Cash Interest Expense
NonCashInterestExpense
0
CY2023Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-180000
CY2022Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2023Q1 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
965000
CY2022Q1 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
242000
CY2023Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-3461000
CY2022Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-37000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-322000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1763000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6970000
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-4033000
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-363000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1456000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1093000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2745000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
693000
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-50000
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1591000
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-273000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13381000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25646000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
14000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
909000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-14000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-909000
CY2023Q1 fnch Principal Payments On Capital Lease Obligation
PrincipalPaymentsOnCapitalLeaseObligation
4000
CY2022Q1 fnch Principal Payments On Capital Lease Obligation
PrincipalPaymentsOnCapitalLeaseObligation
9000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
14000
CY2023Q1 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
15000000
CY2022Q1 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
0
CY2023Q1 fnch Payment Of Terminal Fee Obligation And Prepayment Fee
PaymentOfTerminalFeeObligationAndPrepaymentFee
1155000
CY2022Q1 fnch Payment Of Terminal Fee Obligation And Prepayment Fee
PaymentOfTerminalFeeObligationAndPrepaymentFee
0
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-16159000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-29554000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-26550000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
73805000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
135965000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
44251000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
109415000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
202000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
2000
CY2023Q1 fnch Payments For Proceeds From Operating Lease Liabilities
PaymentsForProceedsFromOperatingLeaseLiabilities
0
CY2022Q1 fnch Payments For Proceeds From Operating Lease Liabilities
PaymentsForProceedsFromOperatingLeaseLiabilities
369000
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
574000
CY2023Q1 fnch Remeasurement Of Right Of Use Asset
RemeasurementOfRightOfUseAsset
40000
CY2022Q1 fnch Remeasurement Of Right Of Use Asset
RemeasurementOfRightOfUseAsset
0
CY2023Q1 fnch Other Receivable Recorded For Sale Of Property And Equipment
OtherReceivableRecordedForSaleOfPropertyAndEquipment
43000
CY2022Q1 fnch Other Receivable Recorded For Sale Of Property And Equipment
OtherReceivableRecordedForSaleOfPropertyAndEquipment
0
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41684000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
106931000
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
2567000
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
2484000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
44251000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
109415000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41700000
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
6000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
32882000
CY2023Q1 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
32900000
CY2023Q1 fnch Transfers Between Fair Value Levels
TransfersBetweenFairValueLevels
0
CY2022Q4 fnch Transfers Between Fair Value Levels
TransfersBetweenFairValueLevels
0
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3524000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
25222000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2276000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9286000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1248000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15936000
CY2023Q1 us-gaap Depreciation
Depreciation
1400000
CY2022Q1 us-gaap Depreciation
Depreciation
1300000
CY2023Q1 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
13100000
CY2015Q4 fnch Lessee Operating Lease Leases Area
LesseeOperatingLeaseLeasesArea
25785
CY2021Q1 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
The lease term, as assumed, was from March 2021 through February 2023
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
0
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
31827000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
32752000
CY2023Q1 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
0
CY2022Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
1000
CY2023Q1 fnch Lease Assets
LeaseAssets
31827000
CY2022Q4 fnch Lease Assets
LeaseAssets
32753000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3253000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3431000
CY2023Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
0
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
34255000
CY2023Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
0
CY2022Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
0
CY2023Q1 fnch Lease Liabilities
LeaseLiabilities
36135000
CY2022Q4 fnch Lease Liabilities
LeaseLiabilities
37692000
CY2023Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
4000
CY2022Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
9000
CY2022Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
2000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1723000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
339000
CY2023Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
13000
CY2022Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
108000
CY2023Q1 us-gaap Variable Lease Cost
VariableLeaseCost
445000
CY2022Q1 us-gaap Variable Lease Cost
VariableLeaseCost
495000
CY2023Q1 us-gaap Sublease Income
SubleaseIncome
1053000
CY2022Q1 us-gaap Sublease Income
SubleaseIncome
0
CY2023Q1 us-gaap Lease Cost
LeaseCost
1132000
CY2022Q1 us-gaap Lease Cost
LeaseCost
953000
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y1M6D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y6M
CY2022Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P0Y2M12D
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.083
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.083
CY2023Q1 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0
CY2022Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.306
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1591000
CY2022Q1 fnch Principal Payments On Capital Lease Obligation
PrincipalPaymentsOnCapitalLeaseObligation
9000
CY2023Q1 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
4567000
CY2023Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
6255000
CY2023Q1 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
6427000
CY2023Q1 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
6186000
CY2023Q1 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
5215000
CY2023Q1 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
21884000
CY2023Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
50534000
CY2023Q1 fnch Interest Portion Of Operating Leases Future Minimum Payments Due
InterestPortionOfOperatingLeasesFutureMinimumPaymentsDue
-14399000
CY2023Q1 fnch Present Value Of Future Minimum Lease Payments
PresentValueOfFutureMinimumLeasePayments
36135000
CY2023Q1 fnch Accrued Research And Development
AccruedResearchAndDevelopment
170000
CY2022Q4 fnch Accrued Research And Development
AccruedResearchAndDevelopment
1967000
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3672000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
5852000
CY2023Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1921000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
880000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1637000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1462000
CY2023Q1 fnch Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
7400000
CY2022Q4 fnch Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
10161000
CY2023Q1 us-gaap Restructuring Charges
RestructuringCharges
3200000
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
100000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
100000
CY2023Q1 us-gaap Cost Maintenance
CostMaintenance
5000000
CY2023Q1 fnch Commitments And Contingencies Due In Next Twelve Months
CommitmentsAndContingenciesDueInNextTwelveMonths
5000000
CY2023Q1 fnch Commitments And Contingencies Due In Next Second Year
CommitmentsAndContingenciesDueInNextSecondYear
20000000
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock entitles the holder to one vote
CY2023Q1 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
0
CY2023Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2276421
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
3560471
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
500000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1180000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2120000
CY2023Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000
CY2022Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
200000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-63939000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-24567000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-63939000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-63939000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-24567000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-24567000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48085547
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48085547
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47528948
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47528948
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.33
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.33
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.52
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.52
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2276421
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4803491

Files In Submission

Name View Source Status
0000950170-23-020080-index-headers.html Edgar Link pending
0000950170-23-020080-index.html Edgar Link pending
0000950170-23-020080.txt Edgar Link pending
0000950170-23-020080-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
fnch-20230331.htm Edgar Link pending
fnch-20230331.xsd Edgar Link pending
fnch-ex31_1.htm Edgar Link pending
fnch-20230331_cal.xml Edgar Link unprocessable
fnch-20230331_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
fnch-20230331_lab.xml Edgar Link unprocessable
fnch-20230331_pre.xml Edgar Link unprocessable
fnch-20230331_htm.xml Edgar Link completed
fnch-ex31_2.htm Edgar Link pending
fnch-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending